Skip to content

Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy

Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02335671
Enrollment
40
Registered
2015-01-12
Start date
2015-02-28
Completion date
2023-01-31
Last updated
2023-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Stage I, Breast Cancer Stage II, Early Stage Breast Cancer

Keywords

Early Stage Breast Cancer, Breast Conserving Surgery, Breast Cancer Stage I, Breast Cancer Stage II

Brief summary

The purpose of this study is to investigate the use of intra-operative Magnetic Resonance Imaging (MRI) and Mass Spectrometry (MS) during breast conserving surgery, and to determine if these tests are capable of accurately predicting the presence or absence of breast tumor in surgical specimens at the margins.

Detailed description

This research study is a Phase II clinical trial investigating the use of intra-operative MRI and MS in breast cancer surgery. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. Investigational means that the intervention is being studied. Prior research has shown that intraoperative MRI and MS are two types of tests that are feasible to use during cancer surgery and may be able to guide therapy. In this study, we are evaluating the accuracy of intra-operative MRI and MS in determining whether or not all cancer tissue was removed during breast surgery.

Interventions

PROCEDUREIntra-operative Magnetic Resonance Imaging (MRI)
OTHERMass Spectrometer Analysis of Tissue Sample

Analysis of Tissue Sample

Sponsors

Dana-Farber Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients must be female * Participants must have a pre-operative standard mammogram with or without ultrasound. These may be performed at outside institutions. * Participants must have biopsy confirmed and clinical stage 1 or stage 2 breast carcinoma. If biopsy was done at an outside hospital, pathology will be reviewed at BWH/DFCI. * Participants must be candidates for definitive local therapy with breast conserving therapy (this takes into account tumor to breast size ratio appropriate for BCS, and the ability to undergo standard radiation therapy post-operatively). * Patient must meet standard MRI guidelines and be able and willing to undergo MRI * Age ≥18 years and \< 75. * Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

* Participants with a known BRCA 1 or 2 mutation. * Participants with known Li-Fraumeni or Cowden's Disease. * Participants with prior mantle radiation. * Participants with locally advanced breast cancer such as inflammatory breast cancer or cancer grossly involving skin. * Participants who are pregnant. * Participants who enroll in a preoperative therapy trial or who have been treated with neoadjuvant chemotherapy. * Participants with known active collagen vascular disease. * Participants with prior history of ipsilateral breast carcinoma. * Patients who have biopsy confirmed multi-centric disease. * Participants who have documented contra-indications for contrast-enhanced MRI, including but not limited to renal failure. * Participants who exceed the weight limit for the surgical table at AMIGO, 350 lbs or who will not fit into the 70 cm diameter bore of the MRI scanner at AMIGO or the 60 cm diameter bore of the pre-procedure imaging MRI scanner.

Design outcomes

Primary

MeasureTime frame
To evaluate the accuracy of MRI in detecting tumor boundaries2 Years

Secondary

MeasureTime frame
To determine the operating characteristics (sensitivity, specificity, negative predictive value and positive predictive value) of MRI in detecting tumor boundaries as confirmed with pathologic results2 Years
To evaluate the correlation of intraoperative mass spectrometry results to tumor boundaries as confirmed with pathologic results.2 Years
To develop novel image processing algorithms to detect remnant tumor from intraoperative DCE-MRI in presence of tissue edema and reduced perfusion2 Years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026